Voro Therapeutics and Alloy Therapeutics Enter Strategic Research Collaboration to Advance Next-Gen Masked TCE Therapeutics

“T-cell engagers have shown tremendous promise, but their broader impact has been constrained by the same challenge facing many powerful immune therapies: how to deliver potency without unacceptable systemic toxicity,” said Ugur Eskiocak, Ph.D., Co-Founder and CEO of Voro Therapeutics. “We believe tumor-activated T-cell engagers represent the next evolution of the field. By combining Voro’s PrimeBody platform and TCE design expertise with Alloy’s discovery and multispecific engineering capabilities, we aim to create highly potent, tumor-selective therapies that broaden access for patients.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib